Research Topics
| Joel R LexchinSummaryAffiliation: York University Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Sponsorship bias in clinical researchJoel Lexchin
School of Health Policy and Management, York University, Toronto, ON, Canada
Int J Risk Saf Med 24:233-42. 2012..Pharmaceutical companies fund the vast majority of the clinical research that is undertaken on medications but face a conflict of interest between producing good science and results that will enhance the sales of their products...
Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviewsDanielle Bishop
Graduate Program in Health, York University, Toronto, Canada
BMC Health Serv Res 13:88. 2013..Coverage with evidence development (CED) is being employed to meet these challenges...- Models for financing the regulation of pharmaceutical promotionJoel Lexchin
School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada
Global Health 8:24. 2012..However, it involves an initial outlay of money that is currently not being spent and many national governments, in both rich and poor countries, are unwilling to incur extra costs... - Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medicationsJoel Lexchin
School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON, M3J 1P3, Canada
Sci Eng Ethics 18:247-61. 2012..What will be needed to curb and ultimately stop the bias that we have seen is a paradigm change in the way that we treat the relationship between pharmaceutical companies and the conduct and reporting of clinical trials... - International comparison of assessments of pharmaceutical innovationJoel Lexchin
School of Health Policy and Management, York University, Toronto, Ontario, Canada
Health Policy 105:221-5. 2012.... 
Harmony in drug regulation, but who's calling the tune? An examination of regulatory harmonization in health CanadaJoel Lexchin
School of Health Policy and Management, York University, Toronto, ON, Canada
Int J Health Serv 42:119-36. 2012..Harmonization could be of benefit to Canada, but the evidence to date suggests that Health Canada been harmonizing down rather than up...- National evaluation of policies on individual financial conflicts of interest in Canadian academic health science centersJoel Lexchin
School of Health Policy and Management, York University, Toronto, ON, Canada
J Gen Intern Med 23:1896-903. 2008..Conflicts of interest (COI) in research are an important emerging topic of investigation and are frequently cited as a serious threat to the integrity of human participant research... - Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating studyJoel Lexchin
School of Health Policy and Management, York University, Toronto, ON M3J 1P3, Canada
Ann Pharmacother 40:2216-22. 2006..Since the early- to mid-1990s, drug companies have paid fees for a variety of activities carried out by the Therapeutic Products Directorate in Canada and the Therapeutic Goods Administration in Australia... - Medicine reimbursement recommendations in Canada, Australia, and ScotlandJoel Lexchin
School of Health Policy and Management, York University, 4700 Keele St, Toronto, Ontario, Canada M3J 1P3
Am J Manag Care 14:581-8. 2008.... - Commercial influence and the content of medical journalsJoel Lexchin
School of Health Policy and Management, York University, Toronto, ON, Canada
BMJ 332:1444-7. 2006 - Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit FormularyJoel Lexchin
School of Health Policy and Management, York University, 4700 Keele St, Toronto, ON M3J 1P3, Canada
Health Policy 91:142-7. 2009..This paper investigates the pricing strategy (perfect flat pricing, perfect monotonic pricing, intermediate) used for multiple dosage medications listed in the Ontario Drug Benefit Formulary... - One step forward, one step sideways? Expanding research capacity for neglected diseasesJoel Lexchin
School of Health Policy and Management, York University, 4700 Keele St, Toronto ON M3J 1P3, Canada
BMC Int Health Hum Rights 10:20. 2010..This conclusion is relevant not just for the most neglected diseases such as leishmaniasis but even for global diseases such as cancer and cardiovascular disease... - Clinical trials in Canada: whose interests are paramount?Joel Lexchin
School of Health Policy and Management, York University, Toronto, ON, Canada
Int J Health Serv 38:525-42. 2008..If clinical trials are to serve the purpose for which they are designed, developing reliable and objective information about new drugs, then commercial interests cannot be allowed to take precedence over health interests... - Bigger and better: how Pfizer redefined erectile dysfunctionJoel Lexchin
School of Health Policy and Management, York University, Toronto, Ontario, Canada
PLoS Med 3:e132. 2006 - Is there still a role for spontaneous reporting of adverse drug reactions?Joel Lexchin
School of Health Policy and Management, York University, Toronto, Ont
CMAJ 174:191-2. 2006 - Canada's patented medicine notice of compliance regulations: balancing the scales or tipping them?Joel Lexchin
School of Health Policy and Management, York University, 4700 Keele St, Toronto Ontario M3J 1P3, Canada
BMC Health Serv Res 11:64. 2011..The regulations tied the regulatory approval of generic medicines to the patent status of the original brand-name product... - Implications of pharmaceutical industry funding on clinical researchJoel R Lexchin
School of Health Policy and Management, York University, Canada
Ann Pharmacother 39:194-7. 2005..Finally, commercially funded clinical research is more likely to yield positive results than when funding comes from other sources. Possible solutions are explored... - Coverage with evidence development for pharmaceuticals: a policy in evolution?Joel Lexchin
School of Health Policy and Management, York University, Toronto, ON, Canada
Int J Health Serv 41:337-54. 2011..Until these policy issues have been addressed, CED will have difficulty achieving its potential... - The danger of imperfect regulation: OxyContin use in the United States and CanadaJoel Lexchin
School of Health Policy and Management, York University and Emergency Physician, University Health Network, Department of Family and Community Medicine, University of Toronto, Toronto, Ontario
Int J Risk Saf Med 23:233-40. 2011..We then look at the association between promotion and the misuse and abuse of OxyContin in both countries. Finally, we advance specific recommendations for regulating promotion for drugs that may have a high abuse potential... - The effect of generic competition on the price of brand-name drugsJoel Lexchin
Emergency Department, University Health Network, Toronto, Ont, Canada
Health Policy 68:47-54. 2004..Literature from the US has shown that brand-name manufacturers do not compete on price once generic competitors become available. This study was undertaken to investigate if this is also true in Canada... - Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here?Joel Lexchin
School of Health Policy and Management, York University, Toronto
Int J Health Serv 35:237-56. 2005..The article concludes with some alternative recommendations on the future of IPRs... - Qualitative research and the politics of knowledge in an age of evidence: developing a research-based practice of immanent critiqueEric Mykhalovskiy
York University, Toronto, ON, Canada
Soc Sci Med 67:195-203. 2008..The latter include challenges to managerial claims about neo-liberal health reform and broadening the evidentiary terrain upon which interlocutors can participate in public debate about health care restructuring... - Drug withdrawals from the Canadian market for safety reasons, 1963-2004Joel Lexchin
School of Health Policy and Management, York University, Emergency Department, University Health Network, Toronto, ON
CMAJ 172:765-7. 2005 - Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory pricesJoel Lexchin
School of Health Policy and Management, York University, Toronto, Ont
CMAJ 174:1120-1. 2006 - Are drugs too expensive in Canada? YesJoel Lexchin
School of Health Policy and Management, York University, Toronto, Ont
Can Fam Physician 52:573-6, 578-81. 2006 - Effects of restrictive formularies in the ambulatory care settingJoel Lexchin
School of Health Policy and Management, York University, Toronto, Canada
Am J Manag Care 8:69-76. 2002..To determine the consequences of restrictive formularies in the ambulatory care setting in 4 areas: overall drug expenditures, overall healthcare spending, changes in the quality of prescribing, and health outcomes... - Rebuttal: are drugs too expensive in Canada?Joel Lexchin
School of Health Policy and Management, York University, Toronto, Ont
Can Fam Physician 52:841-2, 843-5. 2006 - A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differencesJoel Lexchin
School of Health Policy and Management, York University, 4700 Keele St, Toronto, Ont, and Emergency Department, University Health Network, Canada
Health Policy 79:214-20. 2006..This study uses a convenience sample of new drugs marketed in the United States and determines how many of these products are initially unavailable in Canada and their therapeutic value... - Assessing the quality of drug detailingWilliam Molloy
Geriatric Research Group, McMaster University, Hamilton Health Sciences, Henderson Site, 711 Concession Street, Ontario, Canada
J Clin Epidemiol 55:825-32. 2002..64, P <.0001, presentation time, F(2, 118) = 9.98, P <.0001, pharmaceutical representative, F(4, 118) = 9.58, P <.0001, and physician rating the detail, F(109, 118) = 1.94, P <.0001... - Transparency in drug regulation: mirage or oasis?Joel Lexchin
Emergency Department, University Health Network, School of Health Policy and Management, York University, Toronto, Ont
CMAJ 171:1363-5. 2004 - Stop the merry-go-roundJoel Lexchin
School of Health Policy and Management, York University Toronto, Ontario, Canada
Healthc Pap 4:29-34. 2004..A full public pharmacare plan with first-dollar coverage will increase public expenditures but reduce overall drug costs and distribute benefits more equitably... - New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?Joel Lexchin
School of Health Policy and Management at York University, Toronto, Ont
Can Fam Physician 48:1487-92. 2002..To determine how many randomized controlled trials on the safety or efficacy of new drugs are published when these drugs are first marketed in Canada, and to determine the quality of the information in those trials... - The secret things belong unto the Lord our God: secrecy in the pharmaceutical arenaJoel Lexchin
School of Health Policy and Management, York University
Med Law 26:417-30. 2007..By treating data on efficacy and safety as commercially confidential information they effectively collude with industry in denying health professionals and the public access to essential information to be able to use drugs appropriately... - Pharmaceutical industry sponsorship and research outcome and quality: systematic reviewJoel Lexchin
School of Health Policy and Management, York University, Toronto, ON, Canada M3J 1P3
BMJ 326:1167-70. 2003.... - Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidenceJoel Lexchin
School of Health Policy and Management at York University, Toronto, Canada
Int J Health Serv 34:101-22. 2004..Cost sharing also leads to patients foregoing essential medications and to a decline in health care status... - Poor reporting of scientific leadership information in clinical trial registersMelanie Sekeres
Kunin Lunenfeld Applied Research Unit, Baycrest, Toronto, Ontario, Canada
PLoS ONE 3:e1610. 2008..Identifying those scientifically responsible for trial conduct increases accountability. The objective is to examine the proportion of registered clinical trials providing valid scientific leadership information... - Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agenciesJoel Lexchin
York University, Toronto, Canada
Soc Sci Med 70:643-7. 2010..Under this model COI would be prohibited on the grounds that it might influence the outcome of regulatory decisions... - Physician awareness of drug cost: a systematic reviewG Michael Allan
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada, 2 Institute of Health Economics, Edmonton, Alberta, Canada
PLoS Med 4:e283. 2007..We designed this systematic review to investigate doctors' knowledge of the relative and absolute costs of medications and to determine the factors that influence awareness...